Sec Form 4 Filing - Lin Xichen @ Structure Therapeutics Inc. - 2024-06-03

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lin Xichen 2. Issuer Name and Ticker or Trading Symbol Structure Therapeutics Inc. [ GPCR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CHIEF SCIENTIFIC OFFICER (Last) (First) (Middle) C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900 3. Date of Earliest Transaction (MM/DD/YY) 06/03/2024 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 06/03/2024 M 106,200 A $ 0.34 191,907 D Ordinary Shares 06/03/2024 C 106,200 ( 1 ) D $ 0 85,707 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share Option (right to buy) $ 0.34 06/03/2024 M 106,200 ( 2 ) 09/10/2029 Ordinary Shares 106,200 $ 0 213,800 ( 3 ) D American Depositary Shares ( 4 ) 06/03/2024 C 35,400 ( 5 ) ( 4 ) ( 4 ) Ordinary Shares 106,200 $ 0 35,400 D American Depositary Shares ( 4 ) 06/03/2024 S 17,700 ( 6 ) ( 4 ) ( 4 ) Ordinary Shares 53,100 $ 45 17,700 D American Depositary Shares ( 4 ) 06/03/2024 S 17,700 ( 6 ) ( 4 ) ( 4 ) Ordinary Shares 53,100 $ 50.004 ( 7 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lin Xichen C/O STRUCTURE THERAPEUTICS INC. 601 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA94080 CHIEF SCIENTIFIC OFFICER Signatures /s/ Jun Yoon, Attorney-in-Fact 06/05/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Ordinary Shares were converted into American Depositary Shares as reported in Table II above. ( 2 )1/4 of the shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. ( 3 )This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 106,200 Ordinary Shares. ( 4 )Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. ( 5 )106,200 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 35,400 American Depositary Shares. ( 6 )The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on December 28, 2023. ( 7 )The weighted average sale price for the transaction reported was $50.004, and the range of prices were between $50.00 and $50.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.